Patient Capital Management LLC Has $20.03 Million Stock Holdings in Precigen, Inc. (NASDAQ:PGEN)

Patient Capital Management LLC lowered its position in shares of Precigen, Inc. (NASDAQ:PGEN) by 0.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 17,881,246 shares of the biotechnology company’s stock after selling 56,448 shares during the quarter. Patient Capital Management LLC owned about 6.11% of Precigen worth $20,027,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of PGEN. BNP Paribas Financial Markets acquired a new stake in Precigen in the 4th quarter worth about $27,000. Envestnet Asset Management Inc. increased its holdings in shares of Precigen by 29.0% during the fourth quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 5,915 shares during the period. Boothbay Fund Management LLC acquired a new stake in shares of Precigen in the fourth quarter valued at approximately $35,000. RPO LLC bought a new stake in shares of Precigen in the fourth quarter valued at approximately $47,000. Finally, Invesco Ltd. grew its position in Precigen by 14.6% during the fourth quarter. Invesco Ltd. now owns 47,307 shares of the biotechnology company’s stock worth $53,000 after buying an additional 6,040 shares in the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

Wall Street Analysts Forecast Growth

PGEN has been the topic of a number of recent research reports. JMP Securities restated a “market outperform” rating and set a $5.00 price objective on shares of Precigen in a research note on Tuesday, January 14th. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Precigen in a research report on Thursday, March 20th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $7.00.

Precigen Trading Down 1.5%

NASDAQ PGEN opened at $1.35 on Wednesday. The firm’s 50 day simple moving average is $1.52 and its 200 day simple moving average is $1.29. The firm has a market capitalization of $398.47 million, a price-to-earnings ratio of -2.45 and a beta of 1.82. Precigen, Inc. has a 1 year low of $0.65 and a 1 year high of $2.17.

Precigen (NASDAQ:PGEN) last released its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.02. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%. The firm had revenue of $1.19 million during the quarter, compared to analysts’ expectations of $1.30 million. On average, equities research analysts forecast that Precigen, Inc. will post -0.32 earnings per share for the current year.

Precigen Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.